Observations: The principal observation included the effect of GLP-1 receptor agonists on the mesolimbic pathways in the central nervous system, the central amygdala, and the GABAergic neurons in the central nervous system
over half of people discontinue GLP-1 therapy within 24 months, and many later restart therapy
The lawsuits claim that Novo Nordisk was aware, or should have been aware, of the potential for these severe side effects but did not provide sufficient warnings to consumers and healthcare professionals
Improved glucose control, reduced visceral fat, better inflammatory signaling, and reduced cardiovascular risk all carry long-term health impact
For the vast majority of people, the metabolic benefits of GLP-1 medicationsreducing the risk of heart disease, stroke, and the complications of type 2 diabetesfar outweigh the very small, theoretical risk of rare thyroid cancers
K.LeggioL